Education
About Us
Working with TipRanks
Follow Us
Regeneron (IT:1REGN)
:1REGN
1REGN Stock Chart & Stats
€501.40
-€2.60(-0.37%)
At close: 4:00 PM EST
€501.40
-€2.60(-0.37%)
Day’s Range― - ―
52-Week Range€400.00 - €932.20
Previous CloseN/A
Volume0.00
Average Volume (3M)38.00
Market Cap
$52.35B
Enterprise Value€52.23B
Total Cash (Recent Filing)$7.47B
Total Debt (Recent Filing)$2.71B
Price to Earnings (P/E)13.8
Beta0.53
Next Earnings
Oct 28, 2025EPS Estimate
8.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.05
Shares Outstanding104,170,296
10 Day Avg. Volume45
30 Day Avg. Volume38
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue3.67
Enterprise Value/Gross Profit4.48
Enterprise Value/Ebitda9.63
Forecast
1Y Price Target
$627.07Price Target Upside25.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
Bulls Say, Bears Say
Bulls Say
Market PositionThe Sandoz aflibercept biosimilar launch agreement reads as an incremental positive for Regeneron shares, notably delaying launch of the product to 4Q26.
Product ApprovalFDA has granted approval to Libtayo as the first and only immunotherapy for the adjuvant treatment of cutaneous squamous cell carcinoma in patients with a high risk of recurrence following surgery and radiation.
Research And DevelopmentRegeneron is considered a blue-chip biotech with a good R&D track record and various sources of long-term pipeline optionality that could be important.
Bears Say
Clinical Trial ChallengesRegeneron previously announced a significantly higher rate of discontinuation for the triplet combination of semaglutide + trevogrumab + garetosmab due to tolerability, with n=2 deaths in patients with cardiovascular risk.
Medicare ExposureREGN’s high Medicare Part B exposure could create an issue under an MFN framework.
Product CompetitionEylea faces multiple headwinds including competition from branded and biosimilar products.
Regeneron News
1REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was €400.00 and its highest was €932.20 in the past 12 months.
What is Regeneron’s market cap?
Regeneron’s market cap is $52.35B.
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Oct 28, 2025 which is in 11 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Aug 07, 2025. The company reported €11.045 earnings per share for the quarter, beating the consensus estimate of €7.224 by €3.821.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron does not currently pay dividends.
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is 8.28.
How many shares outstanding does Regeneron have?
Regeneron has 104,170,296 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of €11.045 in its last earnings report, beating expectations of €7.224. Following the earnings report the stock price went up 0.546%.
Which hedge fund is a major shareholder of Regeneron?
Currently, no hedge funds are holding shares in IT:1REGN
Regeneron Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$627.07 (25.06% Upside)
$627.07 (25.06% Upside)
Blogger Sentiment
Bullish
IT:1REGN Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.05%
12-Months-Change
Fundamentals
Return on Equity
15.34%
Trailing 12-Months
Asset Growth
5.91%
Trailing 12-Months
Company Description
Regeneron
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
1REGN Company Deck
1REGN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Regeneron showed strong performance in key products like Dupixent and Libtayo, successful launches, and robust financial results, offsetting the declines in EYLEA sales and regulatory delays. The company's significant R&D investments indicate a focus on future growth, despite facing competitive pressures and market dynamics.View all IT:1REGN earnings summaries1REGN Revenue Breakdown
53.72% Net product sales
42.65% Collaboration revenue
3.63% Other
1REGN Stock 12 Month Forecast
Average Price Target
€627.07
▲(25.06% Upside)
Technical Analysis
Options Prices
Currently, No data available
---